Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRSMW9)

• DTT Name: Glycogen synthase kinase-3 beta (GSK-3B) DTT Info
• UniProt ID: GSK3B_HUMAN
• Gene Name: GSK3B

Molecule-Related Drug & Molecule List

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[1]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[2]
Lithium	DMZ3OU6	Fragile X syndrome	LD55	Phase 2	[3]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[4], [5]
Tideglusib	DME4LA1	Osteosarcoma	2B51	Phase 2	[6]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[7]

5 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[8]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[9]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[10]
PMID26161698-Compound-18	DM6JVR5	N. A.	N. A.	Patented	[11]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[12]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD-1080	DMIM9N1	Alzheimer disease	8A20	Discontinued in Phase 1	[13]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[14]
SAN-61	DMGUA9Y	Alzheimer disease	8A20	Terminated	[15]

74 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(2'Z,3'E)-7-Azaindirubin-3'-oxime	DMUIOAP	Discovery agent	N.A.	Investigative	[16]
(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	DMHKXPM	Discovery agent	N.A.	Investigative	[17]
12,13-DEHYDRO-8-O-ACETYLMANZAMINE A	DMVP39I	Discovery agent	N.A.	Investigative	[18]
12,13-DEHYDROMANZAMINE A	DM8XAWU	Discovery agent	N.A.	Investigative	[18]
3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	DM8WL21	Discovery agent	N.A.	Investigative	[19]
3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione	DM6T5K4	Discovery agent	N.A.	Investigative	[20]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[21]
4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	DMJKUQI	Discovery agent	N.A.	Investigative	[8]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[22]
6-deoxymanzamine X	DMKPWN0	Discovery agent	N.A.	Investigative	[18]
8-O-(4-bromobenzenesulfonyl)manzamine F	DMDRPLA	Discovery agent	N.A.	Investigative	[18]
8-O-(4-chlorobenzenesulfonyl)manzamine F	DM48JMC	Discovery agent	N.A.	Investigative	[18]
8-O-(4-toluenesulfonyl)manzamine A	DM249GI	Discovery agent	N.A.	Investigative	[18]
8-OH-MANZAMINE A	DM4QYEF	Discovery agent	N.A.	Investigative	[23]
9-N-ETHYL-8-ETHOXY-MANZAMINE A	DMPXLEU	Discovery agent	N.A.	Investigative	[18]
9-N-METHYL-8-METHOXY-MANZAMINE A	DM1YUBX	Discovery agent	N.A.	Investigative	[18]
alsterpaullone 2-cyanoethyl	DMDI2KH	Discovery agent	N.A.	Investigative	[24]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[25]
AS-601245	DMQ95EB	Discovery agent	N.A.	Investigative	[26]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[10]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[27]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[28]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[28]
CHIR-98014	DMVEBT6	Discovery agent	N.A.	Investigative	[9]
CHIR-98023	DMFBW1H	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[27]
CP-70949	DMBQTZG	Diabetic complication	5A2Y	Investigative	[29]
CT-98024	DM6F8DM	Discovery agent	N.A.	Investigative	[14]
DM-204	DMSXI6W	Solid tumour/cancer	2A00-2F9Z	Investigative	[29]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[30]
GSK-3beta inhibitor II	DMQR7TZ	Discovery agent	N.A.	Investigative	[31]
GSK-3beta inhibitor XI	DM734QB	Discovery agent	N.A.	Investigative	[32]
I-5	DM1TQ7N	Discovery agent	N.A.	Investigative	[33]
IM-12	DM58DGY	Discovery agent	N.A.	Investigative	[34]
indirubin deriv. 8a	DMYLVQF	Discovery agent	N.A.	Investigative	[35]
K00244	DM2BKU8	Discovery agent	N.A.	Investigative	[36]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[37]
LEUCETTAMINE B	DMFQEWM	Discovery agent	N.A.	Investigative	[38]
MANZAMINE A	DMB3GNC	Discovery agent	N.A.	Investigative	[39]
Manzamine E	DMOI9RT	Discovery agent	N.A.	Investigative	[23]
Manzamine Y	DMC7ADZ	N. A.	N. A.	Investigative	[23]
N,8-diphenyl-9H-purin-6-amine	DMZXF36	Discovery agent	N.A.	Investigative	[19]
N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	DMDCX5O	Discovery agent	N.A.	Investigative	[17]
N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	DMKGBZA	Discovery agent	N.A.	Investigative	[17]
N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	DMDQEZG	Discovery agent	N.A.	Investigative	[17]
N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	DM4M12J	Discovery agent	N.A.	Investigative	[17]
N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	DM8JLR4	Discovery agent	N.A.	Investigative	[17]
N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	DMRGQTM	Discovery agent	N.A.	Investigative	[17]
N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	DM3FOKL	Discovery agent	N.A.	Investigative	[40]
N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	DM4GRK8	Discovery agent	N.A.	Investigative	[17]
N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	DMNRSYP	Discovery agent	N.A.	Investigative	[17]
N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	DMMHD9Z	Discovery agent	N.A.	Investigative	[17]
N-(6-benzyl-1H-indazol-3-yl)butyramide	DM0OCLU	Discovery agent	N.A.	Investigative	[17]
N-(6-bromo-1H-indazol-3-yl)butyramide	DMJPL7E	Discovery agent	N.A.	Investigative	[17]
N-(6-chloro-1H-indazol-3-yl)butyramide	DMHGXPY	Discovery agent	N.A.	Investigative	[17]
N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	DMIN128	Discovery agent	N.A.	Investigative	[17]
N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	DMJV3UO	Discovery agent	N.A.	Investigative	[40]
N-(6-phenethyl-1H-indazol-3-yl)butyramide	DM9K4WP	Discovery agent	N.A.	Investigative	[17]
N-(6-phenyl-1H-indazol-3-yl)butyramide	DMVCPLU	Discovery agent	N.A.	Investigative	[40]
N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	DMHFPE3	Discovery agent	N.A.	Investigative	[19]
Neo-kauluamine	DM6D0JC	Discovery agent	N.A.	Investigative	[23]
NU-6102	DMMOFKD	Discovery agent	N.A.	Investigative	[41]
PAULLONE	DMQA8N3	Discovery agent	N.A.	Investigative	[14]
PF-228	DM32FKD	Discovery agent	N.A.	Investigative	[42]
PMID19115845C89S	DMB9F2L	Discovery agent	N.A.	Investigative	[43]
PYRAZOLOPYRIDAZINE 1	DMKTB5U	Discovery agent	N.A.	Investigative	[44]
PYRAZOLOPYRIDAZINE 2	DMI7AUJ	Discovery agent	N.A.	Investigative	[44]
Quinoxaline1	DMRWXH4	Discovery agent	N.A.	Investigative	[24]
RGB-286147	DMP08BY	Discovery agent	N.A.	Investigative	[24]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[27]
SB-415286	DMMAL3I	Discovery agent	N.A.	Investigative	[8]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[27]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[10]
TWS-119	DMS29M4	Discovery agent	N.A.	Investigative	[45]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [3] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [4] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [5] Activating the Wnt/beta-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.
• [6] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [7] Company report (Neurim Pharmaceuticals)
• [8] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [9] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [10] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [11] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [12] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [13] AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.J Neurochem.2013 May;125(3):446-56.
• [14] Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
• [16] Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod. 2009 Dec;72(12):2199-202.
• [17] Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9.
• [18] Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
• [19] Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93.
• [20] Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem. 2008 Jan 15;16(2):636-43.
• [21] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [22] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [23] Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40.
• [24] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [25] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [26] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [27] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [28] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
• [30] Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
• [31] Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8.
• [32] Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem. 2004 Jun 15;12(12):3167-85.
• [33] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [34] Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95.
• [35] Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
• [36] The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
• [37] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [38] Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10.
• [39] 2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem. 2008 Jul 15;16(14):6702-6.
• [40] Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9.
• [41] Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
• [42] Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
• [43] First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
• [44] N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30.
• [45] Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84.